3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Hodgkin Disease
3
Breast Neoplasms
3
Lymphoma, Non-Hodgkin
2
Leukemia
2
Triple Negative Breast Neoplasms
1
Teratoma
1
Rhabdomyosarcoma
1
Renal Pelvis and Ureter Urothelial Carcinoma
1
Recurrence
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Pain
1
Lymphoma, T-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, AIDS-Related
1
Lymphoma
1
Inflammatory Breast Neoplasms
1
Infiltrating Bladder Urothelial Carcinoma
1
Glioma
1
Choriocarcinoma
1
Central Nervous System Neoplasms
1
Carcinoma, Embryonal
1
Burkitt Lymphoma
1
Adenocarcinoma, Bronchiolo-Alveolar
1
Adenocarcinoma of Lung
1
Interventions
pembrolizumab
2
durvalumab
2
Paclitaxel
2
Nivolumab
2
Ipilimumab
2
Doxorubicin
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
talazoparib
1
spartalizumab
1
selinexor
1
sarilumab
1
pexidartinib
1
pertuzumab
1
pazopanib
1
patritumab
1
olaparib
1
niraparib
1
neratinib
1
ganitumab
1
dostarlimab
1
cemiplimab
1
balstilimab
1
abemaciclib
1
Trastuzumab
1
Standard of Care
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Hemangiosarcoma
×
pegfilgrastim
×
90 days
×
Clear all
No trials found.